Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fang Fan

Showing results (611-620 of 614) with videos related to

Pageof 62
Sort By:
You have reached the last page of results.This site can display upto 614 results.
The Lancet. Oncology|December 13, 2021
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patientsChristina Yau, Marie Osdoit, Marieke van der Noordaa, et al.
Gut|July 3, 2026
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation studyYan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, et al.
Communications Biology|June 4, 2021
Wolfberry genomes and the evolution of Lycium (Solanaceae)You-Long Cao, Yan-Long Li, Yun-Fang Fan, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 62

Showing results (611-620 of 614) with videos related to

Sort By:
Pageof 62
You have reached the last page of results.This site can display upto 614 results.
The Lancet. Oncology|December 13, 2021
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patientsChristina Yau, Marie Osdoit, Marieke van der Noordaa, et al.
Gut|July 3, 2026
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation studyYan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, et al.
Communications Biology|June 4, 2021
Wolfberry genomes and the evolution of Lycium (Solanaceae)You-Long Cao, Yan-Long Li, Yun-Fang Fan, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 62